

Junichiro Watanabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2024977/publications.pdf>

Version: 2024-02-01

91
papers

6,608
citations

331259

21
h-index

114278

63
g-index

93
all docs

93
docs citations

93
times ranked

7659
citing authors

#	ARTICLE	IF	CITATIONS
1	Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 724-734.	13.9	1,658
2	Pembrolizumab for Early Triple-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 810-821.	13.9	1,542
3	Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 122-131.	13.9	1,033
4	Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2394-2405.	13.9	764
5	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1688-1700.	5.1	451
6	Comparison of FDG PET and SPECT for Detection of Bone Metastases in Breast Cancer. <i>American Journal of Roentgenology</i> , 2005, 184, 1266-1273.	1.0	124
7	A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. <i>British Journal of Cancer</i> , 2019, 120, 475-480.	2.9	92
8	Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. <i>British Journal of Cancer</i> , 2009, 101, 1676-1682.	2.9	87
9	Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer?. <i>European Radiology</i> , 2011, 21, 2261-2267.	2.3	85
10	Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 2352-2363.	1.2	62
11	Is evaluation of the presence of prepectoral edema on T2-weighted with fat-suppression 3T breast MRI a simple and readily available noninvasive technique for estimation of prognosis in patients with breast cancer?. <i>Breast Cancer</i> , 2014, 21, 684-692.	1.3	51
12	High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin but not with treatment of physician's choice in the EMBRACE study. <i>Breast Cancer</i> , 2020, 27, 706-715.	1.3	41
13	Is lymphovascular invasion degree one of the important factors to predict neoadjuvant chemotherapy efficacy in breast cancer?. <i>Breast Cancer</i> , 2011, 18, 309-313.	1.3	34
14	Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 629-636.	1.1	32
15	Should breast MRI be performed with adjustment for the phase in patients' menstrual cycle? Correlation between mammographic density, age, and background enhancement on breast MRI without adjusting for the phase in patients' menstrual cycle. <i>European Journal of Radiology</i> , 2012, 81, 1539-1542.	1.2	30
16	Brain metastasis in patients with metastatic breast cancer in the real world: a single-institution, retrospective review of 12-year follow-up. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 169-179.	1.1	29
17	Real-time virtual sonography examination and biopsy for suspicious breast lesions identified on MRI alone. <i>European Radiology</i> , 2016, 26, 1064-1072.	2.3	26
18	Phase I study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 407-414.	1.1	24

#	ARTICLE	IF	CITATIONS
19	Background enhancement of mammary glandular tissue on breast dynamic MRI: imaging features and effect on assessment of breast cancer extent. <i>Breast Cancer</i> , 2012, 19, 259-265.	1.3	24
20	Eribulin monotherapy improved survivals in patients with ER-positive HER2-negative metastatic breast cancer in the real world: a single institutional review. <i>SpringerPlus</i> , 2015, 4, 625.	1.2	24
21	A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 211-220.	1.1	24
22	Evaluation of Breast Edema Findings at T2-weighted Breast MRI Is Useful for Diagnosing Occult Inflammatory Breast Cancer and Can Predict Prognosis after Neoadjuvant Chemotherapy. <i>Radiology</i> , 2021, 299, 53-62.	3.6	24
23	First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours. <i>Investigational New Drugs</i> , 2013, 31, 108-114.	1.2	21
24	Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?. <i>European Radiology</i> , 2020, 30, 3363-3370.	2.3	20
25	Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 986-996.	2.3	20
26	Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>Cancer Science</i> , 2017, 108, 987-994.	1.7	18
27	Can T2-weighted 3-T breast MRI predict clinically occult inflammatory breast cancer before pathological examination? A single-center experience. <i>Breast Cancer</i> , 2014, 21, 115-121.	1.3	17
28	Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. <i>Investigational New Drugs</i> , 2017, 35, 791-799.	1.2	16
29	Clip placement after an 11-gauge vacuum-assisted stereotactic breast biopsy: correlation between breast thickness and clip movement. <i>Breast Cancer</i> , 2012, 19, 30-36.	1.3	15
30	Expansive hematoma in delayed cerebral radiation necrosis in patients treated with T-DM1: a report of two cases. <i>BMC Cancer</i> , 2016, 16, 391.	1.1	15
31	Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 81-87.	1.1	15
32	Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 5771-5780.	3.2	15
33	Metastatic breast carcinoma of the abdominal wall muscle: a case report. <i>Breast Cancer</i> , 2015, 22, 206-209.	1.3	14
34	Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 911-917.	1.1	14
35	Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 162, 501-510.	1.1	13
36	Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. <i>In Vivo</i> , 2017, 31, 493-500.	0.6	13

#	ARTICLE	IF	CITATIONS
37	MRI-detected breast lesions: clinical implications and evaluation based on MRI/ultrasonography fusion technology. Japanese Journal of Radiology, 2019, 37, 685-693.	1.0	12
38	Leptomeningeal Metastasis in ER ⁺ /HER2- Advanced Breast Cancer Patients: A Review of the Cases in a Single Institute Over a 15-year Period. Breast Cancer Research and Treatment, 2021, 189, 225-236.	1.1	12
39	Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan. Cancer Chemotherapy and Pharmacology, 2013, 71, 1427-1433.	1.1	10
40	Autologous Stem Cell Transplantations for Recurrent Adult T Cell Leukaemia/Lymphoma Using Highly Purified CD34+ Cells Derived from Cryopreserved Peripheral Blood Stem Cells. Leukemia and Lymphoma, 2001, 42, 1115-1117.	0.6	8
41	An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2014, 73, 623-630.	1.1	8
42	Profiting from IoT: the key is very-large-scale happiness integration. , 2015, , .		7
43	Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial. Breast Cancer Research and Treatment, 2017, 161, 473-482.	1.1	7
44	Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy?. Breast Cancer, 2021, 28, 1120-1130.	1.3	6
45	Abstract P1-18-12: A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer. , 2020, , .		6
46	Hepatic Arterial Infusion Chemotherapy for Metastatic Breast Cancer Patients With Resistance to Standard Systemic Chemotherapies. In Vivo, 2020, 34, 275-282.	0.6	5
47	Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumours. Annals of Oncology, 2019, 30, v116-v117.	0.6	4
48	Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody [®] , as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours. Annals of Oncology, 2019, 30, ix28-ix29.	0.6	4
49	Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy. In Vivo, 2020, 34, 1377-1386.	0.6	4
50	A global phase III clinical study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients. Annals of Oncology, 2017, 28, v80-v81.	0.6	3
51	A call for global harmonization of phase I oncology trials: Results from two parallel, first-in-human phase I studies of DS-7423, an oral PI3K/mTOR dual inhibitor in advanced solid tumors conducted in the United States and Japan.. Journal of Clinical Oncology, 2017, 35, 2536-2536.	0.8	3
52	Phase I Clinical Trial of Ds-7423, an Oral Pi3K/Mtor Dual Inhibitor, in Japanese Patients with Advanced Solid Tumors. Annals of Oncology, 2014, 25, iv153.	0.6	2
53	Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials. British Journal of Cancer, 2018, 118, 1571-1579.	2.9	2
54	Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer. Breast Cancer Research and Treatment, 2020, 182, 513-514.	1.1	2

#	ARTICLE	IF	CITATIONS
55	The Real-world Outcomes of Patients With Advanced Invasive Lobular Carcinoma of the Breast Compared With Invasive Ductal Carcinoma: A Review at a Single Institution. <i>Anticancer Research</i> , 2021, 41, 4619-4627.	0.5	2
56	Abstract P5-18-16: A Multicenter Phase 2 Study (JO22997) Evaluating the Efficacy and Safety of Trastuzumab Emtansine in Japanese Patients With Heavily Pretreated HER2-Positive Metastatic Breast Cancer. , 2012, , .		2
57	Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study. <i>BMC Cancer</i> , 2022, 22, 31.	1.1	2
58	An Unusual Association of Monoclonal Gammopathy, Paroxysmal Nocturnal Haemoglobinuria and Myelodysplastic Syndrome Transformed into Acute Myeloid Leukaemia: Coexistence of Triple Clonal Disorders. <i>Leukemia and Lymphoma</i> , 2001, 42, 813-817.	0.6	1
59	5067 POSTER A Phase 1 Study of Neratinib in Combination With Vinorelbine in Japanese Patients With Advanced or Metastatic Solid Tumours. <i>European Journal of Cancer</i> , 2011, 47, S350.	1.3	1
60	PO100 LONG-TERM BONE MANAGEMENT BY BISPSPHONATE IN METASTATIC BREAST CANCER PATIENTS. <i>Breast</i> , 2013, 22, S53.	0.9	1
61	Is the overall survival after hormone therapy for hormone-receptor-positive, HER2-negative metastatic breast cancer still better than for triple-negative metastatic breast cancer?. <i>Annals of Oncology</i> , 2016, 27, vi82.	0.6	1
62	Imaging features of breast cancer with marked hemosiderin deposition: A case report. <i>European Journal of Radiology Open</i> , 2019, 6, 302-306.	0.7	1
63	ADVANCED INVASIVE LOBULAR CARCINOMA, REAL WORLD EXPERIENCES IN SINGLE INSTITUTION. <i>Breast</i> , 2019, 48, S57.	0.9	1
64	Abstract P1-12-01: Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase III study (JO21095). , 2012, , .		1
65	Abstract OT1-01-01: A phase II, open-label, multicenter, translational study for biomarkers of eribulin mesylate: Evaluation of the utility of monitoring epithelial-to-mesenchymal transition (EMT) markers on tumor cells in the malignant plural effusion of patients with metastatic breast cancer (EXPECT-study). <i>Cancer Research</i> . 2017, 77, OT1-01-01-OT1-01-01.	0.4	1
66	Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study. <i>Scientific Reports</i> , 2021, 11, 21454.	1.6	1
67	5065 POSTER Trastuzumab Responder Will Show Good Repose to Lapatinib. <i>European Journal of Cancer</i> , 2011, 47, S349-S350.	1.3	0
68	1252 POSTER First Report of the Safety, Tolerability, and Pharmacokinetics of Saracatinib (AZD0530) in Japanese Patients With Advanced Solid Tumours. <i>European Journal of Cancer</i> , 2011, 47, S160.	1.3	0
69	Chronology of HER2 disease. <i>Breast</i> , 2011, 20, S39-S40.	0.9	0
70	Phase I Study of Ombrabulin, a Vascular Disrupting Agent (VDA), Administered Every 3 Weeks to Japanese Patients with Advanced Solid Tumors. <i>Annals of Oncology</i> , 2012, 23, xi110.	0.6	0
71	PO69 ERIBULIN IN PRACTICE, REVIEW OF 70 CASES FROM SINGLE INSTITUTE AND COMPARISON WITH JAPAN PHASE 2 STUDY. <i>Breast</i> , 2013, 22, S43-S44.	0.9	0
72	Eribulin in Her2 Negative Metastatic Breast Cancer, Assessment of Overall Survival in Real World. <i>Annals of Oncology</i> , 2014, 25, iv130.	0.6	0

#	ARTICLE	IF	CITATIONS
73	PO60 THE ROLE OF LAPATINIB IN THE MANAGEMENT OF HER2-POSITIVE METASTATIC BREAST CANCER: A REVIEW OF A SINGLE INSTITUTION'S EXPERIENCE DURING THE TRASTUZUMAB AND LAPATINIB ERA. Breast, 2015, 24, S42.	0.9	0
74	1858 The improvement of overall survivals in patients with metastatic breast cancer by zoledronic acid: The assessment of the real world. European Journal of Cancer, 2015, 51, S284-S285.	1.3	0
75	Does the Choice of First-Line Chemotherapy Influence the Outcome of ER+HER2: Metastatic Breast Cancer?. Breast, 2017, 36, S61.	0.9	0
76	Eribulin mesylate for HER2- metastatic breast cancer; analyses of pattern of disease progression and outcomes from the real world. Annals of Oncology, 2017, 28, x31.	0.6	0
77	Durable complete response in HER2-positive breast cancer: A multicenter retrospective analysis. Annals of Oncology, 2017, 28, v101.	0.6	0
78	The utility of risk factors proposed in a prospective clinical trial in the management of ER-positive, HER2-negative metastatic breast cancer patients: Feedback from the real world. Annals of Oncology, 2017, 28, x31.	0.6	0
79	Clinical utility of hepatic arterial infusion chemotherapy for heavily pretreated metastatic breast cancer patients: A review of a single institution. Annals of Oncology, 2018, 29, viii101-viii102.	0.6	0
80	Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2 ⁻) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET). Annals of Oncology, 2018, 29, ix13-ix14.	0.6	0
81	Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2 ⁻) advanced breast cancer (ABC). Annals of Oncology, 2018, 29, ix14-ix15.	0.6	0
82	Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience. Annals of Oncology, 2018, 29, ix20.	0.6	0
83	147P Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours. Annals of Oncology, 2020, 31, S68-S69.	0.6	0
84	Breast cancer leptomeningeal metastasis.. Journal of Clinical Oncology, 2011, 29, e11524-e11524.	0.8	0
85	Lapatinib plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.. Journal of Clinical Oncology, 2011, 29, e11003-e11003.	0.8	0
86	P4-17-11: Central Nervous System Involvement and Clinical Outcome, Review of 135 Patients, 9-Year Follow Up.. , 2011, , .		0
87	Abstract P6-07-16: Evaluation of circulating tumor cell as a marker of prognosis and efficacy in a randomized phase III study in HER2 negative metastatic breast cancer patients treated with capecitabine and docetaxel: JO21095 study. , 2012, , .		0
88	Abstract P6-16-06: Impact of early detection of brain metastasis in metastatic breast cancer patients: A single institutional experience. , 2015, , .		0
89	Early-onset neutropenia-related events in eribulin monotherapy: A possible biomarker in the real world?. Journal of Clinical Oncology, 2017, 35, e12529-e12529.	0.8	0
90	Abstract P1-17-09: Leptomeningeal disease in ER+HER2- metastatic breast cancer patients: A review of the cases in a single institute over a 14-year period. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
91	Abstract P1-10-25: The prognostic and predictive roles of the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio in HER2-negative metastatic breast cancer patients treated with paclitaxel-bevacizumab. , 2020, , .		0